{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T10:12:18Z","timestamp":1773569538884,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.transci.2011.01.015","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T09:25:53Z","timestamp":1298366753000},"page":"173-178","source":"Crossref","is-referenced-by-count":6,"title":["Radioimmunotherapy in follicular lymphoma: Some like it hot\u2026"],"prefix":"10.1016","volume":"44","author":[{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2011.01.015_b0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.transci.2011.01.015_b0010","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the National LymphoCare Study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.transci.2011.01.015_b0020","first-page":"17","article-title":"Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131-Lm1 monoclonal antibody","volume":"1","author":"DeNardo","year":"1988","journal-title":"Antibody Immunoconjugates Radiopharmaceuticals"},{"key":"10.1016\/j.transci.2011.01.015_b0025","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine-131-tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0030","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131-tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphoma","volume":"30","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0035","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131-tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0040","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","article-title":"The radioisotope contributes significantly to the activity of radioimmunotherapy","volume":"23","author":"Davis","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.transci.2011.01.015_b0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131-Tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.015_b0185","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0055","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0060","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium-90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2011.01.015_b0065","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by 131I-tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: 5-year followup of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0190","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","article-title":"Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study","volume":"20","author":"Link","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0075","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0080","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0195","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90\u2013ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0090","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.transci.2011.01.015_b0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.transci.2011.01.015_b0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2011.01.015_b0105","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labed anti-CD20 antibody and autologous stem cell rescue","volume":"16","author":"Liu","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0110","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.015_b0115","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","article-title":"High dose yttrium-90\u2013ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation","volume":"26","author":"Devizzi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0120","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.015_b0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of Iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin\u2019s lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0130","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90 ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.015_b0135","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous stem cell transplantation in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"27","author":"Winter","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V110.11.22.22","article-title":"90-Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA phase II study","volume":"110","author":"Gisselbrecht","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.015_b0145","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/cncr.24801","article-title":"Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas","volume":"116","author":"Palanca-Wessels","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2011.01.015_b0150","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1182\/blood-2008-11-187401","article-title":"A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations","volume":"113","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.015_b0155","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"Goldenberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0160","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0165","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myelogenous leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.transci.2011.01.015_b0170","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","article-title":"Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin\u2019s lymphoma","volume":"20","author":"Ansell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.015_b0175","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.21606","article-title":"Subsequent therapy can be administered after tositumomab and iodine-131 tositumomab for non-Hodgkin\u2019s lymphoma","volume":"106","author":"Dosik","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2011.01.015_b0180","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1200\/JCO.2005.01.0892","article-title":"Retreatment with I-131 tositumomab in patients with non-Hodgkin\u2019s lymphoma who had previously responded to I-131 tositumomab","volume":"23","author":"Kaminski","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050211000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050211000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T20:23:01Z","timestamp":1592338981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050211000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1473050211000310"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2011.01.015","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}